Drugmaker Mylan is promising to double the eligibility for its EpiPen assistance program following a pricing backlash from consumers, but company stopped shorted of reducing or capping prices of the emergency allergy treatment. WSJ’s Austen Hufford joins Lunch Break with Tanya Rivero. Photo: Reuters
